Adds $8.5M in Venture Funding
Autifony Starts Phase I Work in Hearing Loss, Tinnitus
By Nuala Moran
Wednesday, June 12, 2013
LONDON Autifony Therapeutics Ltd. has started Phase I development of AUT00063, its treatment for age-related hearing loss and tinnitus, and raised a further £5.5 million (US$8.5 million) to take that lead program through to clinical proof of concept.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.